Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | http://dx.doi.org/10.1136/jnnp-2020-325302 http://hdl.handle.net/1843/55236 https://orcid.org/0000-0001-5346-8254 https://orcid.org/0000-0003-2095-0786 https://orcid.org/0000-0002-7667-9748 https://orcid.org/0000-0003-3862-7397 https://orcid.org/0000-0002-5630-8050 https://orcid.org/0000-0003-1224-5243 https://orcid.org/0000-0002-4885-0181 https://orcid.org/0000-0002-6661-2910 https://orcid.org/0000-0003-1917-9349 https://orcid.org/0000-0002-4255-9617 https://orcid.org/0000-0003-4767-7564 https://orcid.org/0000-0001-9753-8816 https://orcid.org/0000-0003-4494-0195 https://orcid.org/0000-0003-1384-9794 https://orcid.org/0000-0001-7799-8495 https://orcid.org/0000-0002-6140-5584 https://orcid.org/0000-0002-1033-3840 |
Resumo: | The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune encephalitis as a broad category rather than focusing on individual antibody syndromes. Core authors from the Autoimmune Encephalitis Alliance Clinicians Network reviewed literature and developed the first draft. Where evidence was lacking or controversial, an electronic survey was distributed to all members to solicit individual responses. Sixty-eight members from 17 countries answered the survey. The most popular bridging therapy was oral prednisone taper chosen by 38% of responders while rituximab was the most popular maintenance therapy chosen by 46%. Most responders considered maintenance immunosuppression after a second relapse in patients with neuronal surface antibodies (70%) or seronegative autoimmune encephalitis (61%) as opposed to those with onconeuronal antibodies (29%). Most responders opted to cancer screening for 4 years in patients with neuronal surface antibodies (49%) or limbic encephalitis (46%) as opposed to nonlimbic seronegative autoimmune encephalitis (36%). Detailed survey results are presented in the manuscript and a summary of the diagnostic and therapeutic recommendations is presented at the conclusion. |
id |
UFMG_01b9cd6c48febfe04c6bfafc485e56a5 |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/55236 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2023-06-22T21:49:59Z2023-06-22T21:49:59Z2021-08928897907http://dx.doi.org/10.1136/jnnp-2020-3253021468-330Xhttp://hdl.handle.net/1843/55236https://orcid.org/0000-0001-5346-8254https://orcid.org/0000-0003-2095-0786https://orcid.org/0000-0002-7667-9748https://orcid.org/0000-0003-3862-7397https://orcid.org/0000-0002-5630-8050https://orcid.org/0000-0003-1224-5243https://orcid.org/0000-0002-4885-0181https://orcid.org/0000-0002-6661-2910https://orcid.org/0000-0003-1917-9349https://orcid.org/0000-0002-4255-9617https://orcid.org/0000-0003-4767-7564https://orcid.org/0000-0001-9753-8816https://orcid.org/0000-0003-4494-0195https://orcid.org/0000-0003-1384-9794https://orcid.org/0000-0001-7799-8495https://orcid.org/0000-0002-6140-5584https://orcid.org/0000-0002-1033-3840The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune encephalitis as a broad category rather than focusing on individual antibody syndromes. Core authors from the Autoimmune Encephalitis Alliance Clinicians Network reviewed literature and developed the first draft. Where evidence was lacking or controversial, an electronic survey was distributed to all members to solicit individual responses. Sixty-eight members from 17 countries answered the survey. The most popular bridging therapy was oral prednisone taper chosen by 38% of responders while rituximab was the most popular maintenance therapy chosen by 46%. Most responders considered maintenance immunosuppression after a second relapse in patients with neuronal surface antibodies (70%) or seronegative autoimmune encephalitis (61%) as opposed to those with onconeuronal antibodies (29%). Most responders opted to cancer screening for 4 years in patients with neuronal surface antibodies (49%) or limbic encephalitis (46%) as opposed to nonlimbic seronegative autoimmune encephalitis (36%). Detailed survey results are presented in the manuscript and a summary of the diagnostic and therapeutic recommendations is presented at the conclusion.O objetivo deste artigo é avaliar as evidências disponíveis para cada etapa do tratamento da encefalite autoimune e fornecer opinião de especialistas quando houver falta de evidências. O artigo aborda a encefalite autoimune como uma categoria ampla, em vez de focar em síndromes de anticorpos individuais. Os principais autores da Autoimmune Encephalitis Alliance Clinicians Network revisaram a literatura e desenvolveram o primeiro rascunho. Onde faltavam evidências ou havia controvérsias, uma pesquisa eletrônica foi distribuída a todos os membros para solicitar respostas individuais. Sessenta e oito membros de 17 países responderam à pesquisa. A terapia de ponte mais popular foi a redução gradual de prednisona oral escolhida por 38% dos respondentes, enquanto o rituximabe foi a terapia de manutenção mais popular escolhida por 46%. A maioria dos respondedores considerou imunossupressão de manutenção após uma segunda recaída em pacientes com anticorpos de superfície neuronal (70%) ou encefalite autoimune soronegativa (61%) em oposição àqueles com anticorpos onconeuronais (29%). A maioria dos respondedores optou pelo rastreamento do câncer por 4 anos em pacientes com anticorpos de superfície neuronal (49%) ou encefalite límbica (46%) em oposição à encefalite autoimune soronegativa não límbica (36%). Os resultados detalhados da pesquisa são apresentados no manuscrito e um resumo das recomendações diagnósticas e terapêuticas é apresentado na conclusão.Outra AgênciaengUniversidade Federal de Minas GeraisUFMGBrasilHCL - HOSPITAL DAS CLINICASMED - DEPARTAMENTO DE CLÍNICA MÉDICAJournal of Neurology, Neurosurgery and PsychiatryDoenças autoimunes do sistema nervosoRituximabTerapia de imunossupressãoAnticorposDetecção precoce de câncerEncefalite límbicaAutoimmune encephalitisOral prednisone taperRituximabMaintenance therapyMaintenance immunosuppressionNeuronal surface antibodiesSeronegative autoimmune encephalitisOnconeuronal antibodiesCancer screeningLimbic encephalitisAutoimmune encephalitis: proposed recommendations for symptomatic and long-term managementEncefalite autoimune: recomendações propostas para manejo sintomático e de longo prazoinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://jnnp.bmj.com/content/92/8/897Hesham AbboudJohn Calvin ProbascoSarosh R. IraniBeau AncesDavid R BenavidesMichael BradshawPaulo Pereira ChristoRussell C. DaleMireya Fernandez-FournierEoin P. FlanaganAvi GadothPravin GeorgeElena GrebenciucovaAdham JammoulSoon-Tae LeeYuebing LiMarcelo MatielloAnne Marie MorseAlexander Rae-GrantGaleno RojasIan RossmanSarah SchmittArun VenkatesanSteven VerninoSean J. PittockMaarten Titulaerapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/55236/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALAutoimmune encephalitis proposed recommendations for symptomatic and long-term management.pdfAutoimmune encephalitis proposed recommendations for symptomatic and long-term management.pdfapplication/pdf354810https://repositorio.ufmg.br/bitstream/1843/55236/2/Autoimmune%20encephalitis%20proposed%20recommendations%20for%20symptomatic%20and%20long-term%20management.pdf51a625e3f7a09f85d88e1d4cbb6a2bd0MD521843/552362023-06-22 18:49:59.482oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-06-22T21:49:59Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management |
dc.title.alternative.pt_BR.fl_str_mv |
Encefalite autoimune: recomendações propostas para manejo sintomático e de longo prazo |
title |
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management |
spellingShingle |
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management Hesham Abboud Autoimmune encephalitis Oral prednisone taper Rituximab Maintenance therapy Maintenance immunosuppression Neuronal surface antibodies Seronegative autoimmune encephalitis Onconeuronal antibodies Cancer screening Limbic encephalitis Doenças autoimunes do sistema nervoso Rituximab Terapia de imunossupressão Anticorpos Detecção precoce de câncer Encefalite límbica |
title_short |
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management |
title_full |
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management |
title_fullStr |
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management |
title_full_unstemmed |
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management |
title_sort |
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management |
author |
Hesham Abboud |
author_facet |
Hesham Abboud John Calvin Probasco Sarosh R. Irani Beau Ances David R Benavides Michael Bradshaw Paulo Pereira Christo Russell C. Dale Mireya Fernandez-Fournier Eoin P. Flanagan Avi Gadoth Pravin George Elena Grebenciucova Adham Jammoul Soon-Tae Lee Yuebing Li Marcelo Matiello Anne Marie Morse Alexander Rae-Grant Galeno Rojas Ian Rossman Sarah Schmitt Arun Venkatesan Steven Vernino Sean J. Pittock Maarten Titulaer |
author_role |
author |
author2 |
John Calvin Probasco Sarosh R. Irani Beau Ances David R Benavides Michael Bradshaw Paulo Pereira Christo Russell C. Dale Mireya Fernandez-Fournier Eoin P. Flanagan Avi Gadoth Pravin George Elena Grebenciucova Adham Jammoul Soon-Tae Lee Yuebing Li Marcelo Matiello Anne Marie Morse Alexander Rae-Grant Galeno Rojas Ian Rossman Sarah Schmitt Arun Venkatesan Steven Vernino Sean J. Pittock Maarten Titulaer |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Hesham Abboud John Calvin Probasco Sarosh R. Irani Beau Ances David R Benavides Michael Bradshaw Paulo Pereira Christo Russell C. Dale Mireya Fernandez-Fournier Eoin P. Flanagan Avi Gadoth Pravin George Elena Grebenciucova Adham Jammoul Soon-Tae Lee Yuebing Li Marcelo Matiello Anne Marie Morse Alexander Rae-Grant Galeno Rojas Ian Rossman Sarah Schmitt Arun Venkatesan Steven Vernino Sean J. Pittock Maarten Titulaer |
dc.subject.por.fl_str_mv |
Autoimmune encephalitis Oral prednisone taper Rituximab Maintenance therapy Maintenance immunosuppression Neuronal surface antibodies Seronegative autoimmune encephalitis Onconeuronal antibodies Cancer screening Limbic encephalitis |
topic |
Autoimmune encephalitis Oral prednisone taper Rituximab Maintenance therapy Maintenance immunosuppression Neuronal surface antibodies Seronegative autoimmune encephalitis Onconeuronal antibodies Cancer screening Limbic encephalitis Doenças autoimunes do sistema nervoso Rituximab Terapia de imunossupressão Anticorpos Detecção precoce de câncer Encefalite límbica |
dc.subject.other.pt_BR.fl_str_mv |
Doenças autoimunes do sistema nervoso Rituximab Terapia de imunossupressão Anticorpos Detecção precoce de câncer Encefalite límbica |
description |
The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune encephalitis as a broad category rather than focusing on individual antibody syndromes. Core authors from the Autoimmune Encephalitis Alliance Clinicians Network reviewed literature and developed the first draft. Where evidence was lacking or controversial, an electronic survey was distributed to all members to solicit individual responses. Sixty-eight members from 17 countries answered the survey. The most popular bridging therapy was oral prednisone taper chosen by 38% of responders while rituximab was the most popular maintenance therapy chosen by 46%. Most responders considered maintenance immunosuppression after a second relapse in patients with neuronal surface antibodies (70%) or seronegative autoimmune encephalitis (61%) as opposed to those with onconeuronal antibodies (29%). Most responders opted to cancer screening for 4 years in patients with neuronal surface antibodies (49%) or limbic encephalitis (46%) as opposed to nonlimbic seronegative autoimmune encephalitis (36%). Detailed survey results are presented in the manuscript and a summary of the diagnostic and therapeutic recommendations is presented at the conclusion. |
publishDate |
2021 |
dc.date.issued.fl_str_mv |
2021-08 |
dc.date.accessioned.fl_str_mv |
2023-06-22T21:49:59Z |
dc.date.available.fl_str_mv |
2023-06-22T21:49:59Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/55236 |
dc.identifier.doi.pt_BR.fl_str_mv |
http://dx.doi.org/10.1136/jnnp-2020-325302 |
dc.identifier.issn.pt_BR.fl_str_mv |
1468-330X |
dc.identifier.orcid.pt_BR.fl_str_mv |
https://orcid.org/0000-0001-5346-8254 https://orcid.org/0000-0003-2095-0786 https://orcid.org/0000-0002-7667-9748 https://orcid.org/0000-0003-3862-7397 https://orcid.org/0000-0002-5630-8050 https://orcid.org/0000-0003-1224-5243 https://orcid.org/0000-0002-4885-0181 https://orcid.org/0000-0002-6661-2910 https://orcid.org/0000-0003-1917-9349 https://orcid.org/0000-0002-4255-9617 https://orcid.org/0000-0003-4767-7564 https://orcid.org/0000-0001-9753-8816 https://orcid.org/0000-0003-4494-0195 https://orcid.org/0000-0003-1384-9794 https://orcid.org/0000-0001-7799-8495 https://orcid.org/0000-0002-6140-5584 https://orcid.org/0000-0002-1033-3840 |
url |
http://dx.doi.org/10.1136/jnnp-2020-325302 http://hdl.handle.net/1843/55236 https://orcid.org/0000-0001-5346-8254 https://orcid.org/0000-0003-2095-0786 https://orcid.org/0000-0002-7667-9748 https://orcid.org/0000-0003-3862-7397 https://orcid.org/0000-0002-5630-8050 https://orcid.org/0000-0003-1224-5243 https://orcid.org/0000-0002-4885-0181 https://orcid.org/0000-0002-6661-2910 https://orcid.org/0000-0003-1917-9349 https://orcid.org/0000-0002-4255-9617 https://orcid.org/0000-0003-4767-7564 https://orcid.org/0000-0001-9753-8816 https://orcid.org/0000-0003-4494-0195 https://orcid.org/0000-0003-1384-9794 https://orcid.org/0000-0001-7799-8495 https://orcid.org/0000-0002-6140-5584 https://orcid.org/0000-0002-1033-3840 |
identifier_str_mv |
1468-330X |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Journal of Neurology, Neurosurgery and Psychiatry |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
HCL - HOSPITAL DAS CLINICAS MED - DEPARTAMENTO DE CLÍNICA MÉDICA |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/55236/1/License.txt https://repositorio.ufmg.br/bitstream/1843/55236/2/Autoimmune%20encephalitis%20proposed%20recommendations%20for%20symptomatic%20and%20long-term%20management.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 51a625e3f7a09f85d88e1d4cbb6a2bd0 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1803589533003939840 |